Research ArticleClinical Investigation
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild and Dominik Cordier
Journal of Nuclear Medicine April 2024, 65 (4) 573-579; DOI: https://doi.org/10.2967/jnumed.123.266817
Christopher Eigler
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Lisa McDougall
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Andreas Bauman
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Peter Bernhardt
2Department of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden; and
Michael Hentschel
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Kristine A. Blackham
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Guillaume Nicolas
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Melpomeni Fani
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Damian Wild
1Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
Dominik Cordier
3Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Journal of Nuclear Medicine Apr 2024, 65 (4) 573-579; DOI: 10.2967/jnumed.123.266817
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Journal of Nuclear Medicine Apr 2024, 65 (4) 573-579; DOI: 10.2967/jnumed.123.266817